Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of Stock
by Teresa Graham · The Cerbat GemUnited Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,908,251.64. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Edgemond also recently made the following trade(s):
- On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00.
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total value of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Stock Performance
Shares of NASDAQ:UTHR traded down $3.04 on Friday, hitting $571.73. The stock had a trading volume of 417,925 shares, compared to its average volume of 498,630. The firm’s 50 day moving average price is $514.63 and its 200-day moving average price is $483.21. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The company has a market capitalization of $25.06 billion, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.67 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Morgan Stanley lifted their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Wells Fargo & Company raised their price target on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Royal Bank Of Canada boosted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.
Check Out Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of large investors have recently modified their holdings of the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.